cilostazol has been researched along with Arteriosclerosis Obliterans in 7 studies
Arteriosclerosis Obliterans: Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the plasma concentrations of platelet activation markers, microparticles and soluble adhesion molecules in patients with arteriosclerosis obliterans (ASO) and compared the beneficial effects of cilostazol alone and combination therapy of cilostazol and dipyridamole in these patients." | 9.11 | Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. ( Inami, N; Iwasaka, T; Liu, Y; Nomura, S, 2004) |
| "The novel synthetic antithrombotic drug, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-qui nolinone, OPC-13013) was orally administered in a dose of 200 mg/day to 4 patients with arteriosclerosis obliterans (ASO) in the lower extremities to evaluate the hemodynamic effects of the drug." | 7.67 | Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. ( Sakuma, M; Tanabe, T; Yasuda, K, 1985) |
| " The measurement of digital skin temperatures by infrared thermography provided a noninvasive means to individualize the dosage of cilostazol and to monitor the cilostazol effect and patient complicance during long-term administration." | 2.67 | Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. ( Furukawa, H; Murakami, T; Uchikawa, T, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nikuhinikov, PI | 1 |
| Bytsay, AN | 1 |
| Lysak, LI | 1 |
| Yatsenko, AI | 1 |
| Abramenko, AV | 1 |
| Mii, S | 1 |
| Guntani, A | 1 |
| Kawakubo, E | 1 |
| Tanaka, K | 1 |
| Kyuragi, R | 1 |
| Landi, A | 1 |
| Nomura, S | 2 |
| Inami, N | 1 |
| Iwasaka, T | 1 |
| Liu, Y | 1 |
| Imamura, A | 1 |
| Okuno, M | 1 |
| Kamiyama, Y | 1 |
| Fujimura, Y | 1 |
| Ikeda, Y | 1 |
| Fukuhara, S | 1 |
| Uchikawa, T | 1 |
| Murakami, T | 1 |
| Furukawa, H | 1 |
| Yasuda, K | 1 |
| Sakuma, M | 1 |
| Tanabe, T | 1 |
1 review available for cilostazol and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[Secondary prevention and conservative therapy of obliterative arteriosclerosis].
Topics: Arteriosclerosis Obliterans; Cilostazol; Clinical Trials as Topic; Epoprostenol; Exercise; Hematolog | 2004 |
2 trials available for cilostazol and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole.
Topics: Aged; Arteriosclerosis Obliterans; Biomarkers; Case-Control Studies; Cell Adhesion Molecules; Cilost | 2004 |
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis Obliterans; Cilostazol; Diabetic Angiopathies; Female; Fingers; Humans | 1992 |
4 other studies available for cilostazol and Arteriosclerosis Obliterans
| Article | Year |
|---|---|
[[Impact of plestazol preparation on hyperplasia of inter vascular layer in the patients, suffering obliterating atherosclerosis of the lower extremities arteries after reconstructive operations].]
Topics: Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Biomarkers; Case-Control Studies; Cilostazol; | 2016 |
Cilostazol Improves Wound Healing in Patients Undergoing Open Bypass for Ischemic Tissue Loss: A Propensity Score Matching Analysis.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Blood Vessel Prosthesis Implantation; C | 2018 |
Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines.
Topics: Aged; Arteriosclerosis Obliterans; Biomarkers; Blood Platelets; Blood Vessel Prosthesis Implantation | 2000 |
Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans.
Topics: Aged; Arteriosclerosis Obliterans; Azoles; Cilostazol; Fibrinolytic Agents; Hemodynamics; Humans; Ma | 1985 |